Category Archives: Psoriasis

This article was originally published here

Transfus Apher Sci. 2021 Jun 26:103200. doi: 10.1016/j.transci.2021.103200. Online ahead of print.

ABSTRACT

Psoriasis is a chronic inflammatory skin disease that is characterized by well-demarcated erythematous plaques with a silver scale. Although many new and emerging therapeutic agents are often sufficient to control the disease, there is still a need for alternative treatment options in challenging cases. Extracorporeal photopheresis (ECP) has been applied to many T-cell-mediated diseases to restore immune homeostasis and treat psoriasis effectively. In this paper, we present a psoriasis patient who did not respond to methotrexate, narrowband ultraviolet B, or acitretin. Because of a diagnosis of non-Hodgkin lymphoma, the patient had contraindications for cyclosporine, fumaric acid esters, and biologics but achieved remission with a total of 12 sessions of ECP in two and a half months. Although exacerbation was recorded after polymerase chain reaction (PCR) confirmed coronavirus 2019 (COVID-19) disease infection at the end of the first month, scores from the psoriasis area severity index (PASI) and dermatological life quality index (DLQI) were regressed significantly within two and a half months. ECP seems to provide an effective and rapid response for psoriasis and should be considered for psoriasis patients who fail to respond or have contraindications to existing treatments.

PMID:34215520 | DOI:10.1016/j.transci.2021.103200

Read this article:
A case of psoriasis successfully treated by extracorporeal photopheresis during COVID-19 pandemic - DocWire News

Around 30% of patients with psoriasis also develop psoriatic arthritis with symptoms such as joint pain, stiffness and swelling.

The Western Diet (WD), in particular, can lead to a rapid and detrimental impact on microbial community and function, contributing to systemic inflammation and other metabolically compromised phenotypes, the authors write.

Among the numerous factors known to influence gut microbiota composition, dietary composition has repeatedly been shown to be one of the most critical modifiable factors regulating the gut microbiota.

Tests have shown that a diet rich in sugar and fat induce spontaneous skin inflammation and therefore increase the odds of developing psoriasiform dermatitis (PsD). Gut microbiota is known to play a key part in controlling inflammation. Disruption of gut microbiome by external factors, such as a poor diet, promotes overproduction of harmful pathogens, destabilizes the immune system, and subsequently leads to inflammatory disease.

Perturbation of the gut microbiome by environmental factors such as diet promotes the overgrowth of harmful pathobionts, disrupts immune homeostasis, and leads to the development of inflammatory diseases, they explain.

The team used a mouse model to study the effects of WD on microbial imbalance (dysbiosis) and associated skin and joint inflammation. They also analysed whether dietary changes could reverse symptoms of dysbiosis.

The study included two groups of mice that were exposed to a short-term WD or Chow diet (CD) and subsequently injected with 10 g of interleukin-23 minicircle DNA (IL-23 MC DNA) - a protein linked to inflammatory autoimmune reactions - to induce psoriasis-like skin and joint conditions. The effects of IL-23 exposure were analysed and the results recorded.

Initial findings revealed the CD-fed group developed psoriatic inflammation but presented no other noteworthy symptoms. However, the second group (fed a WD) developed severe gut problems and the majority perished after two weeks. The IL-23 MC DNA dose was halved as a result, to ensure the WD-fed mice would tolerate treatment.

After a further six weeks on their respective diets the two groups were injected with IL-23 MC DNA or with a control. Their diets were maintained for another four weeks.

The researchers noted that after six weeks (before MC DNA delivery) the mice on the WD gained more weight than CD-fed mice and at 10 weeks WD intake led to higher weight gain in the control group. There was no significant weight gain in the IL-23 MC DNA treated mice.

Erythema (skin rash) and scaling were observed in the WD + IL-23 MC DNA group but were considerably milder in the CD + IL-23 MC DNA group and absent in the control. The control group also exhibited the least amount of ear swelling.

The data suggests that a WD can lead to increased intestinal permeability (or leaking gut), which has previously been observed in autoimmune diseases, including psoriasis. A loss of microbial diversity was also observed in WD-fed mice. Thus, the authors surmise that modulating gut microbiota was a viable option to help regulate intestinal permeability and control psoriatic inflammation.

Crucially, the researchers observed that a more balanced (CD) diet helped reduce gut dysbiosis and helped restore some balance to the gut microbiome.

Mice that were switched from a WD to a CD after 10 weeks had less scaling and reduced ear and epidermal thickness, compared with those that remained on the WD.

The researchers therefore concluded that the proinflammatory effects of a WD could be partially reversed with dietary changes.

Source: Journal of Investigative Dermatology

Authors: Zhenrui Shi, Xuesong Wu, Clarissa Santos Rocha, Yu-Jui Yvonne Wan, Satya Dandekar, Samuel T. Hwang

Short-Term Western Diet Intake Promotes IL-23-Mediated Skin and Joint Inflammation Accompanied by Changes to the Gut Microbiota in Mice

doi.org/10.1016/j.jid.2020.11.032

See original here:
Switching diet promotes healthy skin and joints, say scientists - NutraIngredients.com

If you have certain inflammatory conditions, your doctor might suggest Cimzia (certolizumab) as a treatment option for you.

Cimzia is a prescription medication thats used in adults to treat:

Cimzia is a type of drug called a tumor necrosis factor blocker. You receive it as an injection under your skin.

This article describes the dosages of Cimzia, including its forms, strength, and how to use the drug. To learn more about Cimzia, see this in-depth article.

Note: This article covers Cimzias typical dosages, which are provided by the drugs manufacturer. But when using Cimzia, always take the dosage that your doctor prescribes.

Cimzia is a medication that youll get as an injection under your skin. Your doctor may give you the injection in their office. Or they can teach you or your caregiver how to give yourself the injection at home.

Cimzia comes in two different forms:

Both forms of Cimzia contain one strength: 200 milligrams (mg).

Your Cimzia dosage will depend on the condition that youre treating. Other factors may include your body weight and how you respond to the treatment.

For most conditions, youll likely start treatment with a higher dose, called the starting dose or loading dose. This helps your body respond faster to the drug.

After a certain amount of time, your doctor may reduce your dose to what is called a maintenance dose. This is the dose that you take long term to keep your symptoms under control.

The information below describes dosages that are commonly used or recommended. But be sure to take the dosage your doctor prescribes for you. Your doctor will determine the best dosage to fit your needs.

For plaque psoriasis, the typical dosage of Cimzia is 400 mg (two injections of 200 mg) once every 2 weeks.

If you weigh less than or equal to 90 kilograms (about 198 pounds), your doctor might reduce your dosage. Specifically, after your first three doses, you may have a 200-mg dose (one injection) once every 2 weeks.

For rheumatoid arthritis and psoriatic arthritis, the typical starting dosage of Cimzia is 400 mg once every 2 weeks.

After three doses at 400 mg, your doctor may switch you to a maintenance dose. This is typically 200 mg, which youll receive once every 2 weeks.

In some cases, your doctor may change your maintenance dosage to 400 mg once every 4 weeks. This would reduce the number of injections you have per month. Do not switch to this dosage without talking with your doctor first.

Ankylosing spondylitis and non-radiographic axial spondyloarthritis are forms of arthritis that affect the spine. For these conditions, the typical starting dosage of Cimzia is 400 mg once every 2 weeks.

After three doses at 400 mg, your doctor may switch you to a maintenance dose. This is typically 200 mg, which youll receive once every 2 weeks. Or it may be 400 mg, received once every 4 weeks.

For Crohns disease, the typical starting dosage of Cimzia is 400 mg once every 2 weeks for three doses.

If your symptoms have eased after this, your doctor will switch you to a maintenance dosage. This will likely be 400 mg once every 4 weeks.

Yes, Cimzia is typically used as a long-term treatment. If you and your doctor determine that Cimzia is safe and effective for you, its likely that youll use it long term.

Here are the answers to some frequently asked questions about Cimzias dosage.

The Food and Drug Administration (FDA) hasnt approved Cimzia to treat ulcerative colitis (a type of inflammatory bowel disease). But Cimzia is being studied to see if it could be effective for this use.

Because Cimzia isnt approved to treat ulcerative colitis, there isnt a recommended dosage for this condition. If youre interested in taking Cimzia to treat ulcerative colitis, talk with your doctor. This would be an off-label use of the drug. (Off-label drug use means using a drug for a purpose other than that approved by the FDA.)

It may take a few weeks before your symptoms start to ease. If you think Cimzia isnt working for you, dont change the dosage of Cimzia that your doctor has prescribed. Talk with your doctor if you have questions about whether Cimzia is working for you.

If you miss an appointment to have an injection of Cimzia, call your doctors office right away to reschedule.

If you usually inject Cimzia yourself and you miss a dose, call your doctors office to find out what to do. They may tell you to take the missed dose as soon as possible. But if its nearly time for your next dose, they may tell you to skip the missed dose.

Your doctor can also tell you if you need to adjust your dosing schedule after a missed dose.

If you need help remembering to take your dose of Cimzia on time, try using a medication reminder. This can include setting an alarm, downloading a reminder app, or setting a timer on your phone. It can also be helpful to write your Cimzia dosing schedule on a calendar.

The dosage of Cimzia youre prescribed may depend on:

If you have any questions about the dosage of Cimzia you should take, talk with your doctor.

Youll receive Cimzia as an injection under your skin. Your doctor can give you Cimzia injections in their office. They can also teach you or your caregiver how to do this at home using Cimzia prefilled syringes.

Youll take Cimzia either once every 2 weeks or once every 4 weeks. And you may need to take one or two injections each time. Always follow your doctors instructions.

You can inject Cimzia into these areas of your body:

Each time you give yourself Cimzia, you should rotate injection sites. This means injecting the drug into a different place in one of the areas mentioned above. Make a note of the date and the area you used for each injection. This way you can avoid injecting in the same place next time.

If you need to take two injections for your dose, the injections should be at least 2.5 centimeters (about 1 inch) apart.

Avoid injecting Cimzia into areas of skin that are tender, red, discolored, bruised, or hard. Also avoid areas where you have scars or stretch marks.

Dont use more Cimzia than your doctor prescribes. Using more than this can lead to serious side effects.

Call your doctor right away if you think youve used too much Cimzia. You can also call 800-222-1222 to reach the American Association of Poison Control Centers, or use its online resource. But if you have severe symptoms, call 911 or your local emergency number immediately, or go to the nearest emergency room.

The sections above describe the typical dosages provided by the drug manufacturer. If your doctor recommends Cimzia for you, they will prescribe the dosage thats right for you.

Remember, you shouldnt change your dosage of Cimzia without your doctors recommendation. Only take Cimzia exactly as prescribed. Talk with your doctor if you have questions or concerns about your current dosage.

Here are some questions you may want to ask your doctor:

You can learn more about the conditions Cimzia treats by subscribing to Healthlines newsletters for psoriasis, inflammatory bowel disease (IBD), and rheumatoid arthritis.

Disclaimer: Healthline has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.

Read more:
Cimzia and Dosage: Strength, Forms, When to Use, and More - Healthline

Severe Psoriasis Marketresearch report is the new statistical data source added byOneup Business Insights.

In 2019, the global Severe Psoriasis Market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2020-2025.

The current environment of the ever-evolving business sector, as well as the existing and prospective implications of COVID-19 on the market, are examined in this research. Each business covered in the research report is examined in terms of product and application portfolios, market share, growth potential, future plans, and development activities such as mergers and acquisitions, product introduction, and so on.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Get sample copy of thisreport @

https://www.oneupbusinessinsights.com/request_sample.php?tname=14569

Top key players @ Amgen, Inc., AbbVie Inc., Novartis AG, Johnson & Johnson, AstraZeneca, Eli Lilly and Company, UCB, Celgene Corporation, Merck

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Severe Psoriasis market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Severe Psoriasis Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key market trends impacting the growth of the Global Severe Psoriasis Market?

What are the challenges to market growth?

Who are the key vendors in the Global Severe Psoriasis Market?

What are the market opportunities and threats faced by the vendors in the Global Severe Psoriasis Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

More Information:

https://www.oneupbusinessinsights.com/enquiry_before_buying.php?tname=14569

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Up to 20% Discount on this Premium Report @

https://www.oneupbusinessinsights.com/askfor_discount.php?tname=14569

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Oneup Business Insights is an obligated organization and a global groundbreaker in research, analytics and advisory. We create advance informative reports that will assist you to transform your business, amend your approach and take decisions valiantly.

Oneup Business Insights is one of the top resellers of market research reports, including market intelligence, data solutions, competitive positioning, and custom intelligence to an array of organizations globally. Our customer portfolio includes business organizations from fortune 500 companies, SMEs, start-ups, financial technology start-ups, and venture capitalists.

We attain particular and niche demand of the industry while stabilize the quantum of standard with specified time and trace crucial movement at both the domestic and universal levels. The particular products and services provided by Oneup Business Insights cover vital technological, scientific and economic developments in industrial, pharmaceutical and high technology companies.

Contact Us:

Vick Batho

(Assistant Manager Business Development)

US: +1 315 675 7779

3811 Ditmars Blvd, Astoria, NY-1115

sales@oneupbusinessinsights.com

http://oneupbusinessinsights.com/

Read the original:
Severe Psoriasis Market 2021 Size, Status and Global Outlook Amgen, Inc., AbbVie Inc., Novartis AG, Johnson & Johnson, AstraZeneca, Eli Lilly and...

Corresponding author Rubn Queiro, MD, PhD, of the Central University Hospital of Asturias, in Spain, and colleagues explained that secukinumab (SEC), a human monoclonal antibody targeting interleukin 17A, had a favorable safety profile in clinical trials. In addition, postmarketing surveillance has shown the therapy has a low frequency of discontinuation.

However, we currently have no consistent data on long-term survival of SEC in patients with AxSpA and PsA in routine clinical practice, the investigators wrote.

They therefore performed a multicenter retrospective observational study of patients with AxSpa or PsA who were prescribed and received at least 1 dose of SEC. The primary end points were AEs and drug retention rates.

Altogether, 154 patients were included in the study: 59 had PsA and the remaining 95 patients had AxSpA. The overall disease duration was 6.5 years, and most of the enrollees (61%) had previously been treated with at least 2 biologics before being prescribed SEC.

After 1 year, the data showed that 66% of patients were still taking SEC. However, by the end of the second year, the retention rate was 43%. Those who quit primarily stopped taking SEC due to lack of efficacy (59%), and 36% said they stopped the therapy because of AEs. Nearly three-quarters (71%) of patients who quit the therapy due to AEs did so in the first 6 months of treatment.

The most common AEs were gastrointestinal (GI) disorders, which occurred in 6 patients and included symptoms such as nausea, vomiting, and abdominal pain. There were 2 cases of Crohn disease. All 6 patients with GI AEs withdrew, as did 4 of 5 patients who reported infections. Five patients had disorders of the skin and subcutaneous tissue, and all 5 withdrew as well.

Queiro and colleagues found a number of factors that made a patient less likely to discontinue SEC, and these included male gender, obesity, hypertension, and diabetes. The investigators said the finding that obesity was linked with better drug survival was interesting, since previous reports have suggested patients who are obese and who have psoriasis tend to have a poor therapeutic response to SEC.

However, we found that obesity, and other components of metabolic syndrome, were predictors of longer survival for SEC therapy, they wrote. Therefore, SEC could be a good therapeutic choice in obese patients with AxSpA and PsA as opposed to [tumor necrosis factor inhibitor] agents.

Factors associated with discontinuation included number of previous biologics and depression.

Queiro and colleagues acknowledged some limitations, including the relatively small sample size and the retrospective nature of the study. They said their findings ought to be replicated in larger cohorts, but that they still show SEC appears to be performing well in clinical practice.

Treatment persistence has been optimal even in third line treatment, independent of underlying disease, and obesity does not seem a marker of poor treatment response, they concluded.

Reference

Alonso S, Villa I, Fernndez S, et al. Multicenter study of secukinumab survival and safety in spondyloarthritis and psoriatic arthritis: SEcukinumab in Cantabria and ASTURias study. Front Med (Lausanne). Published online May 26, 2021. doi:10.3389/fmed.2021.679009

More here:
Secukinumab Retention High in Real-world Study of Patients With PsA, AxSpA - AJMC.com Managed Markets Network

Psoriasis Drug Market Growth Opportunities and Forecast to 2026:

The Global Psoriasis Drug Market industry research report begins with an elementary prologue to Psoriasis Drug showcases alongside product definition, product scope, market overview, product characterization, and specification. The global Psoriasis Drug Market was valued at a billion USD in 2018 and is expected to reach a billion USD by 2026 with an anticipated CAGR of during the forecast period, 20192026. The information mentioned in the Global Psoriasis Drug Market research report presents an overview of the latest trends observed in the global market. Besides, this intelligence study focuses on the latest events such as the technological developments and the product launches and their consequences on the Global Psoriasis Drug Market. Furthermore, the research report presents the potential industry supply, market demand, market value, market competition, key market players and the industry estimate from 2019-2026.

Grab a Free Sample PDF copy of the Psoriasis Drug Market Report 2019 @ https://straitsresearch.com/report/Psoriasis Drug-Market/request-sample

The Major Players Covered in this Report: Amgen Inc., Celgene Corporation, AbbVie Inc., Johnson & Johnson, Novartis, Eli Lilly, AstraZeneca, and Pfizer are some of the key market players.

These players are focusing on expanding their business in developing countries or emerging markets, like India, China, and South Korea, through coalitions and acquisitions for the development of novel products. The development of biosimilars is more commonly adopted By these companies. & More.

A comprehensive analysis of contemporary trends, demand spectrum, growth rate, and key region-wise Psoriasis Drug market exploration has also been embodied in this report. There are speculations about Global Psoriasis Drug Market to strongly dominate the global economy with a substantial growth rate in the coming years. Promptly developing industry infrastructure, increased product commercialization, and drifting demands of the Psoriasis Drug are strengthening Psoriasis Drug industrys footholds to become more influential and significantly contribute in international revenue generation.

The report is a valued asset for the active players, new participants, and future investors, and provides a comprehensive assessment across regions such as:

Growing Domestic Demand and Expanding Pharmaceutical Sector to Drive the Demand for Psoriasis Drug in the APAC RegionAsia-Pacific region is anticipated to hold the largest market share in the global Psoriasis Drug market during the forecast period 2017-2026. The growth in this region can be attributed to the presence of emerging economies like India, China, Japan, Vietnam, and Indonesia, which account for the largest share in this region. India is one of the largest producers of Psoriasis Drug and a major exporter of the product to various countries across the globe. India accounts for around 80% of the worlds exports of Psoriasis Drug. The favorable climatic conditions and growth of agricultural inputs and allied services like cold storage and warehousing in India are prompting higher production.

COVID-19 Impact Analysis: The COVID-19 pandemic had a significant impact on the on trade segment and Industry. Manufacturers are comprehending strategies to revive from the current situation by means of reshaping their sales channels as well as product innovation. The duration of the virus outbreak remains a key factor in assessing the overall impact of the pandemic. However, the global Railway Suspension System industry is expected to stabilize after 2019. The liquor industry was not impacted severely due to the pandemic.

Full Report Link @ https://straitsresearch.com/report/Psoriasis Drug-market

2 Research Methodology2.1 Primary Research2.2 Research Methodology2.3 Assumptions & Exclusions2.4 Secondary Data Sources

3 Executive Summary4 Market Overview4.1 Report Segmentation & Scope4.2 Value Chain Analysis: AR and VR Headset Market4.2.1 Vendor Matrix4.3 Key Market Trends4.3.1 Drivers4.3.2 Restraints4.3.3 Opportunities4.4 Porters Five Forces Analysis4.4.1 Bargaining Power of Suppliers4.4.2 Bargaining Power of Buyers4.4.3 Threat of Substitution4.4.4 Threat of New Entrants4.4.5 Competitive Rivalry4.5 Environment & Regulatory Landscape4.6 Forecast Factors & Relevance of Impact4.7 Macro-Economic & Geopolitical Scenario4.8 Parent Market Overview4.9 Technology Landscape4.10 Market Share Analysis4.11 Potential Venture Analysis4.12 Regional Price Trends4.13 Raw Material Trends4.14 Covid-19 Impact Analysis4.14.1 Pre Covid-19 Market Scenario Analysis4.14.2 Post Covid-19 Market Scenario Analysis4.14.3 Measures Taken by Top Players4.14.4 Quarterly Market Revenue and Growth Forecast till 20194.15 Cost Structure Analysis4.15.1 Labor Cost4.15.2 Consumables4.15.3 Maintenance Cost

5 Type Overview5.1 Introduction5.1.1 Market Size & Forecast (Value & Volume)5.2 AR Headset5.2.1 Market Size & Forecast (Value & Volume)5.3 VR Headset5.3.1 Market Size & Forecast (Value & Volume)5.4 AR/VR Headset5.4.1 Market Size & Forecast (Value & Volume)

6 Product Type Overview6.1 Introduction6.1.1 Market Size & Forecast (Value & Volume)6.2 Standalone6.2.1 Market Size & Forecast (Value & Volume)6.3 Tethered6.3.1 Market Size & Forecast (Value & Volume)6.4 Screenless Viewer6.4.1 Market Size & Forecast (Value & Volume)Continue..

StraitsResearch:(straitsresearch.com) is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & market research reports.

Read the original post:
Trend Expected to Guide Psoriasis Drug Market from 2019-2026: Growth Analysis by Manufacturers, Regions, Type and Application. KSU | The Sentinel...

Psoriasis Marketresearch report is the new statistical data source added byOneup Business Insights.

In 2019, the global Psoriasis Market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2020-2025.

The current environment of the ever-evolving business sector, as well as the existing and prospective implications of COVID-19 on the market, are examined in this research. Each business covered in the research report is examined in terms of product and application portfolios, market share, growth potential, future plans, and development activities such as mergers and acquisitions, product introduction, and so on.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Get sample copy of thisreport @

https://www.oneupbusinessinsights.com/request_sample.php?tname=14579

Top key players @ Eli Lilly and Company, Pfizer Inc., Johnson and Johnson (Janssen Global Services, LLC), Novartis AG, and Amgen Inc.

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Psoriasis market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Psoriasis Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key market trends impacting the growth of the Global Psoriasis Market?

What are the challenges to market growth?

Who are the key vendors in the Global Psoriasis Market?

What are the market opportunities and threats faced by the vendors in the Global Psoriasis Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

More Information:

https://www.oneupbusinessinsights.com/enquiry_before_buying.php?tname=14579

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Up to 20% Discount on this Premium Report @

https://www.oneupbusinessinsights.com/askfor_discount.php?tname=14579

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Oneup Business Insights is an obligated organization and a global groundbreaker in research, analytics and advisory. We create advance informative reports that will assist you to transform your business, amend your approach and take decisions valiantly.

Oneup Business Insights is one of the top resellers of market research reports, including market intelligence, data solutions, competitive positioning, and custom intelligence to an array of organizations globally. Our customer portfolio includes business organizations from fortune 500 companies, SMEs, start-ups, financial technology start-ups, and venture capitalists.

We attain particular and niche demand of the industry while stabilize the quantum of standard with specified time and trace crucial movement at both the domestic and universal levels. The particular products and services provided by Oneup Business Insights cover vital technological, scientific and economic developments in industrial, pharmaceutical and high technology companies.

Contact Us:

Vick Batho

(Assistant Manager Business Development)

US: +1 315 675 7779

3811 Ditmars Blvd, Astoria, NY-1115

sales@oneupbusinessinsights.com

http://oneupbusinessinsights.com/

Continue reading here:
Psoriasis Market 2021-Competitive Insights: Eli Lilly and Company, Pfizer Inc., Johnson and Johnson (Janssen Global Services, LLC), Novartis AG The...

New research shows that switching from a Western diet to a balanced diet could help you reduce skin and joint inflammation. The study led by UC Davis Health researchers states that the reduction may be due to a better-balanced gut microbial culture.

Published in the Journal of Investigative Dermatology, the study suggests that cutting out sugar and fat and consuming a more balanced diet can help you restore gut health, which can suppress skin inflammation that may otherwise contribute to inflammatory skin diseases such as psoriasis.

Psoriasis is a chronic skin condition linked to the bodys immune system. Healthy skin cells are attacked mistakenly by immune cells, which cause skin inflammation and the formation of scales and itchy red patches.

Approximately 30% of patients with psoriasis also have psoriatic arthritis, which causes morning stiffness and fatigue, pain in joints, swollen fingers and toes, and changes to nails.

Previous studies have shown how diet can influence psoriasis through microbial balance in the intestines and skin inflammation. Consuming a traditional Western diet can cause a rapid change to the guts microbial community and its functions. This disruption, called dysbiosis, can contribute to gut inflammation.

For the new study, researchers wanted to test whether intestinal dysbiosis affects skin and joint inflammation. A mouse model was used to study the effects of diet on psoriasis and psoriatic arthritis. The mice were injected with Interleukin-23 (IL-23) minicircle DNA to induce a response mimicking psoriasis-like skin and joint diseases.

IL-23 is a protein created by the immune cells responsible for many inflammatory autoimmune reactions. This includes psoriasis and inflammatory bowel disease (IBD).

Researchers found that a short-term Western diet appears sufficient to cause microbial imbalance and to enhance susceptibility to IL-23 proteins that can lead to skin inflammation.

There is a clear link between skin inflammation and changes in the gut microbiome due to food intake, said Sam T. Hwang, study author. The bacterial balance in the gut disrupted shortly after starting a Western diet, and worsened psoriatic skin and joint inflammation.

The study went on to show that eating a diet high in sugar and fat is a major contributor to skin and joint inflammation. However, it can be changed by switching to a more balanced diet. The improvement in skin inflammation seen in mice taken off the Western diet indicated a short-term impact of the Western diet on skin inflammation.

Researchers concluded the study by suggesting that changes in diet could partially reverse the proinflammatory effects and alteration of gut microbiota caused by the Western diet.

Go here to read the rest:
Study States That Diet Rich in Sugar and Fat Contributes to Skin & Joint Inflammation - Bel Marra Health

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today a collaboration with researchers from the University of Barcelona, led by lead investigator Dr. Luis F Santamaria-Bab, Ph.D. to investigate the modulatory effect of targeted therapies in models of inflammatory skin disease. The research study will use DermTechs Smart StickerTM-enabled platform to interrogate inflammatory pathways underlying the pathogenesis of atopic dermatitis (AD) and psoriasis. In vitro models of AD and psoriasis will also be used to evaluate the modulatory effect of targeted therapies on these inflammatory pathways. The research collaboration highlights DermTechs commitment to using precision genomics and personalized dermatology approaches to improve the identification of effective therapies and better understanding of dermatological diseases.

AD is a chronic inflammatory skin disease characterized by intense itching that affects approximately 15-20% of children and up to 10% of adults in the US and Europe. Psoriasis is an autoimmune skin disease characterized by red, scaly skin lesions formed by the hyperproliferation of epidermal keratinocytes, and it affects approximately 3% of the adult population in the US and Europe. Both AD and psoriasis have significant negative social and economic impacts on patients and their families. The increasing number of therapies for AD and psoriasis in clinical development add to a growing armamentarium for physicians and support the need for more personalized approaches to patient care.

We are very delighted to collaborate in precision dermatology with DermTech, said Dr. Luis F. Santamaria-Bab, Ph.D., Professor of Immunology and head of Translational Immunology Group at the University of Barcelona at the Parc Cientfic de Barcelona.

Through precision genomics, it is now possible to identify complex genetic and immunological factors that play a role in the pathogenesis of inflammatory skin diseases such AD and psoriasis, said Michael Howell, Ph.D., DermTechs chief scientific officer. We believe that this collaboration will increase our understanding of how these targeted therapies work in some patients and provide insight on personalized approaches to treatment for AD and psoriasis.

About DermTech:

DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTechs mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTechs investor relations site at: http://www.dermtech.com.

Forward-Looking Statements:

This press release includes forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as expect, estimate, project, budget, forecast, anticipate, intend, plan, may, will, could, should, believes, predicts, potential, continue, and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, costeffectiveness, commercialization and adoption of DermTechs products and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTechs ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTechs tests; (4) the reimbursement of DermTechs tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTechs products; (6) DermTechs ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTechs products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the Risk Factors section of the most recent Quarterly Report on Form 10-Q filed by DermTech with the Securities and Exchange Commission (the SEC), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Read the original:
DermTech to Partner with University of Barcelona for Research Study on Atopic Dermatitis and Psoriasis - Business Wire

The skin is the largest organ in the body it protects the body from trauma and serves other functions like regulating body temperature. Psoriasis is an autoimmune condition that impacts the skin, presenting itself as red, scaly patches that affect different body parts.

Psoriasis occurs when the immune system attacks healthy skin tissue, but little is known about why this happens.The condition can affect people of any age, and is considered equally prevalent among men and women.

The World Health Organization categorizes psoriasis as a serious global problem that affects at least 10 million people worldwide. Psoriasis is widely considered to be the most stigmatized of all skin disorders.

Researchers and patients with psoriasis point out that misconceptions about the condition decrease the quality of life for people, and note that more awareness is needed on the subject. This has led to initiatives like the Get Your Skin Out Movement and similar body-positive campaigns to understand how psoriasis affects people.

Psoriasis is a long-term condition that presents itself most commonly as a rash on the skin. The most common areas affected by psoriasis include the scalp, knees, and elbows but other parts of the body such as the ears and neck can also be affected.As an autoimmune skin condition, it is the result of an overactive immune system. It causes the skin cells to multiply up to 10 times faster than normal making the skin build up into bumpy redpatches. For some people, these patches itch, burn, and sting.Inflammation caused by psoriasis is also known to impact other organs and tissues in the body.

The WHO recognizes psoriasis as a condition attached with a lot of stigma, thereby associated with a decreased quality of life. People who suffer from psoriasis are at risk of developing mental illnesses such as depression. There are also a range of other associated illnesses such as Inflammatory Bowel Disease (IBD), cardiovascular disease, diabetes, and others.

While the condition is not contagious, there is currently no permanent cure.

While not much is known about what causes psoriasis, environment and genetics play a role in determining who is more vulnerable. Common risk factors include family history, smoking, and stress the latter two are associated with weakened immune systems, and therefore may make one more susceptible to developing the autoimmune condition.

Psoriasis usually presents itself in early adulthood, but people of all ages, skin colors, and genders can experience it.

Related on The Swaddle:

All You Need To Know About Alopecia

Plaque psoriasis is the most common type of psoriasis. The condition occurs in cycles, or flare-ups, of a rash. The average period between each flareup can be anywhere between one to 12 months. Flare-ups usually come with the following symptoms:

There are, however, other types of psoriasis which affect other parts of the body. They have their own symptoms:

As an autoimmune condition, psoriasis is triggered when the immune system mistakes cells of the body as external harmful agents such as bacteria or viruses, and mounts a response against them. The immune system causes inflammation, which in turn triggers faster cell growth. So while healthy skin cells shed and grow every 28-30 days, people with psoriasis experience skin cell growth every 3-4 days. When the skin grows faster than it is shed, the cells build up to form the red scaly appearance which is visible on the skin surface.

Psoriasis is often triggered by certain immune-related or external factors. Triggering events include infections, injuries, and changing lifestyle habits that may impact the immune system, leading to the onset of symptoms.

External elements include skin or throat infections, cold or dry weather, skin injuries, stress, smoking, high alcohol consumption, and certain medications.

Although there is no permanent cure for psoriasis, treatment options exist to manage symptoms and reduce the risk of other associated diseases. Topical treatments in the form of applying medication on the skin, through ointments and creams, help slow down cell reproduction and inflammation.

Phototherapy is another strategy, in which doctors use artificial Ultraviolet B (UVB) light to slow the growth of skin cells. Other therapies that focus on making diet and lifestyle changes are also a way of treating the condition although their success varies from person to person.

Read the original post:
All You Need To Know About Psoriasis - The Swaddle